ClinicalTrials.gg
CompletedNCT00088634Updated Apr 8, 2016Results posted

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

A Phase 2 interventional study of Lurasidone and Placebo in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
18th of 39
180 · median 149
Started
2004
with 1 other
Phase 2
5 of 39
none open now
Registered
3rd of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 18th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 2, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

Read the detailed description

Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from the Positive and Negative Syndrome Scale (PANSS).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Satisfy criteria for schizophrenia as established by SCID-CV
  • The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
  • If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception

Exclusion criteria

Exclusion Criteria:

  • The patient has used an drug within the past 30 days
  • The patient has participated in a previous study of this compound
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Lurasidone

    80 mg AM dosing once daily

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 80 mg AM dosing once daily

  • DrugPlacebo

    Matching Placebo to 40mg lurasidone tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score

    The BPRS consists of 18 ordered categorical items (from "not present" to "extremely severe," on a 1- to 7-point scale), each developed to assess patient symptomatology in a relatively discrete symptom area. The BPRS will be extracted from the PANSS by adding the scores of the 18 items (P2 to P7, N1, N2, and G1 to G10) of the PANSS and will not be assessed separately.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores

    The PANSS is a 30-item scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. Each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme). Scores range from 30-210 with higher scores representing a worsening of schizophrenia.

    Time frame: Baseline and 6 weeks

  2. Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores

    The CGI Severity (CGI-S) assesses the severity of illness of the patient relative to the particular population on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and 6 weeks

  3. Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores

    The MADRS is a 10-item rating scale that assesses apparent and reported sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

    Time frame: Baseline and 6 weeks

07

Results

Posted Mar 1, 2011

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 80 mgPlacebo
Started9090
Completed5247
Not completed3843

Outcome measures

PrimaryChange From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score

The BPRS consists of 18 ordered categorical items (from "not present" to "extremely severe," on a 1- to 7-point scale), each developed to assess patient symptomatology in a relatively discrete symptom area. The BPRS will be extracted from the PANSS by adding the scores of the 18 items (P2 to P7, N1, N2, and G1 to G10) of the PANSS and will not be assessed separately.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score
units on a scaleLurasidone 80 mgPlacebo
Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score-8.9 (-11.5 to -6.2)-4.2 (-6.9 to -1.5)
Statistical analysis
  • Lurasidone 80 mg vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores

The PANSS is a 30-item scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. Each item is rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme). Scores range from 30-210 with higher scores representing a worsening of schizophrenia.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores
units on a scaleLurasidone 80 mgPlacebo
Change From Baseline to the End of the Double-blind Treatment in the PANSS (Positive and Negative Syndrome Scale) Scores-14.1 (-18.3 to -9.9)-5.5 (-9.8 to -1.2)
Statistical analysis
  • Lurasidone 80 mg vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores

The CGI Severity (CGI-S) assesses the severity of illness of the patient relative to the particular population on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores
units on a scaleLurasidone 80 mgPlacebo
Change From Baseline to the End of the Double-blind Treatment in the CGI-S (Clinical Global Impression of Severity) Scores-0.6 (-0.8 to -0.4)-0.2 (-0.4 to 0.0)
Statistical analysis
  • Lurasidone 80 mg vs Placebo · ANCOVA · p = <0.05
SecondaryChange From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores

The MADRS is a 10-item rating scale that assesses apparent and reported sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · units on scale
Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores
units on scaleLurasidone 80 mgPlacebo
Change From Baseline to the End of the Double-blind Treatment in the MADRS (Montgomery Asberg-Depression Scale) Scores-2.9 (-4.6 to -1.3)-0.1 (-1.9 to 1.6)
Statistical analysis
  • Lurasidone 80 mg vs Placebo · ANCOVA · p = <0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 80 mg—2/90 (2.2%)53/90 (58.9%)
Placebo—3/90 (3.3%)37/90 (41.1%)
Most frequent serious events
Most frequent serious events
EventLurasidone 80 mgPlacebo
Schizophrenia NOSPsychiatric disorders2/901/90
Blood Creatine Phosphokinase IncreasedInvestigations0/901/90
Chronic Obstructive Airways DiseaseRespiratory, thoracic and mediastinal disorders0/901/90
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLurasidone 80 mgPlacebo
NauseaGastrointestinal disorders15/903/90
ConstipationGastrointestinal disorders10/905/90
VomitingGastrointestinal disorders10/905/90
HeadacheNervous system disorders10/909/90
SomnolenceNervous system disorders10/903/90
SedationNervous system disorders9/904/90
InsomniaPsychiatric disorders9/903/90
AkathisiaNervous system disorders8/903/90
DyspepsiaGastrointestinal disorders7/903/90
Upper Respiratory Tract InfectionInfections and infestations3/906/90

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lurasidone 80 mgPlaceboTotal
Mean39.7 ± 9.9141.9 ± 9.7840.8 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 80 mgPlaceboTotal
Female222042
Male6870138
08

Study locations

22 sites
  • Birmingham Psychiatry Pharmaceutical
    Birmingham, Alabama 35209, United States
  • Summit Research Group
    Little Rock, Arkansas 72211, United States
  • Comprehensive NeuroScience
    Cerritos, California 90703, United States
  • Collaborative Neuro Science Network, Inc.
    Garden Grove, California 92845, United States
  • Optimum Health Services
    La Mesa, California 91942, United States
  • California Clinical Trials
    San Diego, California 92123, United States
  • CNRI, LLC San Diego
    San Diego, California 92126, United States
  • Pacific Clinical Research
    Upland, California 91786, United States
  • Comprehensive NeuroScience, Inc
    Washington, District of Columbia 20016, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • The Segal Institute
    North Miami, Florida 33161, United States
  • University of South Florida, Department of Psychiatry and Behavioral Medicine
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Comprehensive Neuroscience, Inc.
    Hoffman Estates, Illinois 60194, United States
  • Robert Lynn Horne, MD, Suite 4
    Las Vegas, Nevada 89102, United States
  • CNS Research Institute
    Clementon, New Jersey 08021, United States
  • Quantum Clinical Services Group
    Philadelphia, Pennsylvania 19139, United States
  • Community Clinical Research
    Austin, Texas 78729, United States
  • Future Search Trials
    Austin, Texas 78756, United States
  • Claghorn-Lesem Research Clinic
    Bellaire, Texas 77401, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • CBH Health, L.L.C - Dominion Hospital
    Falls Church, Virginia 22044, United States
09

References and documents

Publications

  • Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2. PubMed 19497249 ↗
  • Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. PubMed 34751928 ↗
  • Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140-7. doi: 10.1017/S1092852914000285. Epub 2014 Jun 23. PubMed 24955752 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2004
First posted
Aug 2, 2004
Start
May 2004
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Results first posted
Mar 1, 2011
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00088634
Responsible party
Sponsor
First posted
Aug 2, 2004
Start date
May 2004
Primary completion
Dec 2004
Completion
Dec 2004
Results posted
Mar 1, 2011
Last update
Apr 8, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion